CAPITAL GROUP BUYS NEARLY 2% STAKE IN LOTUS DEVELOPERS

US-based Capital Group has acquired a nearly 2% stake in Mumbai-based Sri Lotus Developers and Realty, while ChrysCapital-backed Sepia Investments has offloaded more than 4% of its holding in Ahmedabad-based pharmaceutical company Corona Remedies through open-market transactions. Shares of Lotus Developers reacted positively to the deal, briefly hitting the 5% upper circuit at Rs 207.88 on the NSE amid heavy trading volumes. Meanwhile, Corona Remedies recovered sharply from a gap-down opening and ended the session 0.16% higher at Rs 2,200.80. Smallcap World Fund Inc, a fund managed by California-based Capital Group, purchased 95.05 lakh shares of Lotus Developers, representing a 1.94% stake, for Rs 190.01 crore. The shares were acquired at Rs 199.89 apiece. On the selling side, promoter Anand Kamalnayan Pandit offloaded 97.7 lakh shares, equivalent to a 2% stake, for Rs 195.3 crore at Rs 199.90 per share. In Corona Remedies, Sepia Investments, an affiliate of private equity firm ChrysCapital, sold 24.85 lakh shares, representing a 4.06% stake, for Rs 509.6 crore at Rs 2,050.32 per share. The transaction was part of Sepia Investments’ 12.68% holding in the company as of June 2026. Among the buyers, SBI Mutual Fund acquired 15.4 lakh shares, or a 2.51% stake, in Corona Remedies for Rs 315.7 crore. Amundi Funds Asia Equity Concentrated also purchased 3.12 lakh shares.